Opsens 관리

관리 기준 확인 3/4

Opsens CEO는 Louis Laflamme, Jan2013 에 임명되었습니다 의 임기는 10.92 년입니다. 총 연간 보상은 CA$ 425.37K, 76.9% 로 구성됩니다. 76.9% 급여 및 23.1% 보너스(회사 주식 및 옵션 포함). 는 CA$ 1.98M 가치에 해당하는 회사 주식의 0.59% 직접 소유합니다. 1.98M. 경영진과 이사회의 평균 재임 기간은 각각 3.3 년과 9.9 년입니다.

주요 정보

Louis Laflamme

최고 경영자

CA$425.4k

총 보상

CEO 급여 비율	76.9%
CEO 임기	10.9yrs
CEO 소유권	0.6%
경영진 평균 재임 기간	3.3yrs
이사회 평균 재임 기간	9.9yrs

최근 관리 업데이트

Recent updates

Opsens Inc. (TSE:OPS) Just Reported And Analysts Have Been Lifting Their Price Targets

Nov 23

CEO 보상 분석

Louis Laflamme 의 보수는 Opsens 의 수익과 비교하여 어떻게 변경되었나요?
날짜	총 보상	급여	회사 수익
Aug 31 2023	n/a	n/a	-CA$12m
May 31 2023	n/a	n/a	-CA$15m
Feb 28 2023	n/a	n/a	-CA$13m
Nov 30 2022	n/a	n/a	-CA$13m
Aug 31 2022	CA$425k	CA$327k	-CA$11m
May 31 2022	n/a	n/a	-CA$9m
Feb 28 2022	n/a	n/a	-CA$6m
Nov 30 2021	n/a	n/a	-CA$4m
Aug 31 2021	CA$397k	CA$279k	-CA$1m
May 31 2021	n/a	n/a	CA$622k
Feb 28 2021	n/a	n/a	CA$1m
Nov 30 2020	n/a	n/a	-CA$179k
Aug 31 2020	CA$342k	CA$274k	-CA$3m
May 31 2020	n/a	n/a	-CA$5m
Feb 29 2020	n/a	n/a	-CA$6m
Nov 30 2019	n/a	n/a	-CA$5m
Aug 31 2019	CA$566k	CA$254k	-CA$2m
May 31 2019	n/a	n/a	-CA$2m
Feb 28 2019	n/a	n/a	-CA$2m
Nov 30 2018	n/a	n/a	-CA$3m
Aug 31 2018	CA$308k	CA$249k	-CA$5m
May 31 2018	n/a	n/a	-CA$4m
Feb 28 2018	n/a	n/a	-CA$5m
Nov 30 2017	n/a	n/a	-CA$5m
Aug 31 2017	CA$225k	CA$190k	-CA$7m

보상 대 시장: Louis 의 총 보상 ($USD 312.94K ) Canadian 시장에서 비슷한 규모의 회사에 대한 평균보다 낮습니다( $USD 721.11K ).

보상과 수익: 회사가 수익성이 없는 동안 Louis 의 보상이 증가했습니다.

CEO

Louis Laflamme

10.9yrs

테뉴어

CA$425,365

보상

Mr. Louis Laflamme, C.A, C.P.A., serves as Director at Icentia Inc. He had been an Interim Chief Financial Officer of Opsens Inc. since December 09, 2022 until March 27, 2023. He has been the Chief Executi...

리더십 팀

이름	위치	테뉴어	보상	소유권
Alan Milinazzo	Executive Chairman of the Board	4.8yrs	CA$99.20k	0.063% CA$ 210.3k
Louis Laflamme	CEO, President & Director	10.9yrs	CA$425.37k	0.59% CA$ 2.0m
Brad Davis	Chief Commercial Officer	1.8yrs	CA$756.25k	데이터 없음
John Hannigan	Chief Financial Officer	less than a year	데이터 없음	데이터 없음
Pierre Poulin	Corporate Controller	no data	데이터 없음	데이터 없음

3.3yrs

평균 재임 기간

경험이 풍부한 관리: OPS 의 관리팀은 경험 ( 3.3 년 평균 재직 기간)으로 간주됩니다.

이사회 구성원

이름	위치	테뉴어	보상	소유권
Alan Milinazzo	Executive Chairman of the Board	4.8yrs	CA$99.20k	0.063% CA$ 210.3k
Louis Laflamme	CEO, President & Director	10.9yrs	CA$425.37k	0.59% CA$ 2.0m
Jean Lavigueur	Independent Director	11.9yrs	CA$152.64k	0.27% CA$ 899.0k
Denis Sirois	Independent Director	17.2yrs	CA$152.94k	0.38% CA$ 1.3m
Gaetan Duplain	Director	17.2yrs	CA$294.71k	3.31% CA$ 11.1m
James Mackin	Independent Director	7.3yrs	CA$210.38k	0.038% CA$ 126.6k
Denis Harrington	Independent Director	8.9yrs	CA$90.45k	0.017% CA$ 58.0k
Lori Chmura	Independent Director	2.3yrs	CA$136.74k	데이터 없음

9.9yrs

평균 재임 기간

59yo

평균 연령

경험이 풍부한 이사회: OPS 의 이사회는 경험(평균 재직 기간 9.9 년)으로 간주됩니다.

Opsens 관리

관리 기준 확인 3/4

주요 정보

최근 관리 업데이트

Independent Director recently sold CA$79k worth of stock

Insufficient new directors

Opsens Inc., Annual General Meeting, Jan 24, 2023

Opsens Inc. Announces Departure of Robin Villeneuve as Corporate Secretary, Effective December 9, 2022

CFO & Corporate Secretary exercised options to buy CA$115k worth of stock.

CFO & Corporate Secretary exercised options and sold CA$75k worth of stock

Recent updates

Haemonetics Corporation (NYSE : HAE) completed the acquisition of Opsens Inc. (TSX : OPS).

Haemonetics Corporation (NYSE : HAE) completed the acquisition of Opsens Inc. (TSX : OPS).

Haemonetics Corporation (NYSE : HAE) entered into a definitive agreement to acquire Opsens Inc. (TSX : OPS) for CAD 345 million.

New minor risk - Share price stability

Forecast to breakeven in 2025

Opsens Inc. to Report Q3, 2023 Results on Jul 13, 2023

Potential Upside For Opsens Inc. (TSE:OPS) Not Without Risk

New major risk - Financial position

OpSens Inc. Announces Inclusion of Savvywire™ in COMPLETE TAVR Study

Independent Director recently sold CA$79k worth of stock

Second quarter 2023 earnings: EPS and revenues exceed analyst expectations

No longer forecast to breakeven

Consensus forecasts updated

No longer forecast to breakeven

First quarter 2023 earnings: Revenues exceed analyst expectations

Opsens Inc. to Report Q1, 2023 Results on Jan 12, 2023

Opsens Inc. has completed a Follow-on Equity Offering in the amount of CAD 10 million.

Price target decreased to CA$3.73

Consensus EPS estimates fall by 27%

Consensus EPS estimates fall by 21%

Full year 2022 earnings: EPS misses analyst expectations

Opsens Inc. to Report Q4, 2022 Results on Nov 22, 2022

Opsens Inc. to Report Q4, 2022 Results on Nov 22, 2022

Insufficient new directors

Opsens Inc., Annual General Meeting, Jan 24, 2023

Opsens Inc. Announces Departure of Robin Villeneuve as Corporate Secretary, Effective December 9, 2022

Opsens Inc. Announces First Savvywire Clinical Cases in Europe and Launch of Safe-Tavi Study

Opsens Announces First Savvywire Procedure in the United States by Dr. Philippe Genereux of Morristown Medical Center

OpSens Inc. Announces FDA Clearance for the SavvyWire for Use in Transcatheter Aortic Valve Replacement (TAVR) Procedures

Consensus forecasts updated

Third quarter 2022 earnings: Revenues exceed analysts expectations while EPS lags behind

Forecast breakeven date pushed back to 2024

Opsens Inc. to Report Q3, 2022 Results on Jul 14, 2022

CFO & Corporate Secretary exercised options to buy CA$115k worth of stock.

CFO & Corporate Secretary exercised options and sold CA$75k worth of stock

Opsens Inc. Announces New Data Supporting the Safety and Efficacy of its SavvyWire Recently Approved by Health Canada for Transcatheter Aortic Valve Replacement Procedures

Insufficient new directors

Opsens Inc. Announces Health Canada Approval for Its New TAVR Guidewire

Consensus EPS estimates fall by 69%

Second quarter 2022 earnings: EPS in line with expectations, revenues disappoint

Opsens Inc. to Report Q2, 2022 Results on Apr 13, 2022

Insufficient new directors

Insufficient new directors

OpSens Inc Appoints Brad Davis as Chief Commercial Officer

Independent Director exercised options to buy CA$245k worth of stock.

First quarter 2022 earnings: EPS in line with expectations, revenues disappoint

First quarter 2022 earnings: EPS in line with expectations, revenues disappoint

Opsens Inc. Announces 510(K) Submission to U.S. FDA for New Guidewire for the Tavr Procedure

Forecast breakeven date pushed back to 2023

Full year 2021 earnings: EPS exceeds analyst expectations while revenues lag behind

Price target increased to CA$4.28

Opsens Inc. Successfully Completes 20-Patient in Human Clinical Study for TAVR Procedure

Independent Director recently sold CA$139k worth of stock

Independent Director exercised options to buy CA$368k worth of stock.

President exercised options and sold CA$230k worth of stock

Director recently bought CA$310k worth of stock

Director recently bought CA$310k worth of stock

Price target increased to CA$3.79

OPSENS Receives Approval from Health Canada to Initiate First In-Man Clinical Study for its New Guidewire for the TAVR Procedure

Insufficient new directors

Independent Director recently bought CA$150k worth of stock

Independent Director recently bought CA$150k worth of stock

Consensus forecasts updated

Third quarter 2021 earnings released

Opsens (TSE:OPS) Has Debt But No Earnings; Should You Worry?

Price target increased to CA$3.00

Second quarter 2021 earnings released: EPS CA$0.001 (vs CA$0.015 loss in 2Q 2020)

Price target raised to CA$2.56

Opsens Inc. has completed a Follow-on Equity Offering in the amount of CAD 25 million.